Efficacy of Talazoparib

Talazoparib (Talazoparib is approved for patients with deleterious or suspected deleterious germline BRCA mutations (gBRCAm), HER2-negative locally advanced or metastatic breast cancer. The approval is based on the EMBRACA study. All patients have known or suspected deleterious gBRCA mutations and must have received no more than 3 cytotoxic chemotherapy regimens for locally advanced or metastatic disease. The primary efficacy outcome was progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors, with an estimated median PFS of 8.6 months.

Talazopanib is also approved with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer. Efficacy was evaluated in the TALAPRO-2 trial. These patients first underwent orchiectomy and, if not performed, received a gonadotropin-releasing hormone (GnRH) analogue. Patients who had received previous systemic therapy for mCRPC were excluded. The primary efficacy outcome measure was bone-standard radiographic progression-free survival (rPFS). In the HRR gene mutation population, a statistically significant improvement in rPFS was observed in the group receiving the combination therapy compared with the placebo group, with a median of less than 13.8 months.

The original drug of talazopanib has not yet been marketed in China, so it has not been included in medical insurance. The original drug specification of talazopanib listed overseas is 0.25mg*30 capsules, and the price per box may be around RMB 10,000 (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheaper generics of talazopanib overseas. For example, the price of a box of 1mg*30 pills produced by a Laos pharmaceutical factory may be more than 3,000 yuan (the price may fluctuate due to the exchange rate).